Serum prostate-specific antigen (PSA) plays an important role in the screening and diagnosis of prostate cancer (PCa). The recommended PSA cut-off in PCa screening is 4ng/ml. We report two cases of low PSA localized PCa which were incidentally found by computed tomography (CT) taken for another disease.

Androgen deprivation therapy is a standard of care for metastatic prostate cancer, however, eventually, all men relapse. A paradoxical approach utilizing high doses of testosterone in castration-resistant prostate cancer patients demonstrated clinical responses. Here we report on four heavily pretreated CRPC patients successfully treated with supra-physiological doses of testosterone.

A 95-year-old man was diagnosed with left pelvis cancer which presented with rapid tumor growth, multiple metastases, and bilateral tender gynecomastia. Elevated serum human chorionic gonadotropin(hCG), prolactin, estradiol, and progesterone were detected. The patient’s condition rapidly deteriorated and he passed away.

Urinary bladder cancer is frequently multifocal and has a high incidence of recurrence. Although the prostatic urethra is a frequent site of tumor relapse in patients with non-muscle-invasive bladder cancer treated with TURBT, such tumors are often underappreciated. Here we present two cases having urethral recurrence after TURBT.